Vertex Pharmaceuticals Incorporated (VRTX)
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally.
Scored against other Healthcare stocks, not a fixed scale.
The quick read
Vertex Pharmaceuticals is right in the middle: the good and the not-so-good roughly cancel out.
- What's working
- It carries less debt and has more breathing room than most other healthcare companies.
- Worth watching
- Its price is high compared with other healthcare companies, given its sales and profits.
Analyst price target
~12-month · 28 analystsPublished targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain…
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 6,400
- Headquarters
- Boston, MA
Similar stocks
What’s behind the score
Valuation
P/E 28.9 — lower than 57% of Healthcare peers
P/B 6.3 — lower than 32% of Healthcare peers
P/S 10.1 — lower than 10% of Healthcare peers
EV/EBITDA 23.7 — lower than 13% of Healthcare peers
EV/Revenue 9.6 — lower than 13% of Healthcare peers
PEG 2.0 — lower than 33% of Healthcare peers
FCF yield 2.1% — higher than 17% of Healthcare peers
Profitability & quality
Gross margin 55.0% — higher than 37% of Healthcare peers
Operating margin 38.1% — higher than 93% of Healthcare peers
Net margin 35.0% — higher than 100% of Healthcare peers
ROE 23.5% — higher than 81% of Healthcare peers
ROA 11.9% — higher than 86% of Healthcare peers
Free cash flow is 60% of reported net income
Financial health
Debt/equity 0.1 — lower than 89% of Healthcare peers
Current ratio 3.19 — higher than 90% of Healthcare peers
Quick ratio 2.54 — higher than 90% of Healthcare peers
Cash/debt 3.97 — higher than 93% of Healthcare peers
Debt/EBITDA 0.39 — lower than 90% of Healthcare peers
Growth
Revenue growth 12.5% YoY — higher than 73% of Healthcare peers
Earnings growth 8.0% YoY — higher than 31% of Healthcare peers
Ownership & investor activity
Payout ratio 0.0% — somewhat unusual vs Healthcare peers
Net insider buying, +3.0% of insider shares
Institutions net sold, -11.6% of shares held
Insiders hold 0.2% of shares outstanding
2.0% of float sold short
Momentum
Mixed vs its moving averages
61% of the way from its 52-week low to high